Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood markers may predict kidney failure in heart patients

NCT ID NCT07139626

Knowledge-focused Sponsor: Haiyan Pan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether certain proteins in the blood can predict if someone with chronic heart failure will develop kidney problems (cardiorenal syndrome). Researchers will measure these proteins in 150 adults with heart failure and follow them for one year. The goal is to find a simple blood test that gives an early warning, so doctors can step in sooner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be recruited from chronic heart failure (CHF) patients attending the cardiology outpatient clinics or admitted to the cardiology wards of a tertiary care hospital in China. The study focuses on adults with stable CHF(HFrEF, HFmrEF, HFpEF). The hospital is a regional referral center with a high volume of HF cases, ensuring a diverse and representative sample. Eligible patients will be enrolled based on clinical diagnosis and willingness to participate in biomarker analysis and follow-up assessments.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 75 years. * Diagnosed with stable chronic heart failure (HF) according to the 2024 Chinese Heart Failure Diagnosis and Treatment Guideline. * HF subtypes include: HFrEF (LVEF ≤40%), HFmrEF (LVEF 41 - 49%), HFpEF (LVEF ≥50%). * Willing to provide blood samples for biomarker analysis. * Able to comply with follow - up visits and study procedures for 12 months. * Note: For the screening phase, 10 patients will be included for each subtype; for the validation phase, 30 patients will be included for each subtype. Exclusion Criteria: * History of long-term dialysis or kidney surgery. * Acute kidney injury (AKI) within the past 3 months. * Use of nephrotoxic drugs within the past 3 months. * Diagnosis of autoimmune diseases (e.g., lupus, rheumatoid arthritis). * Active malignancy or history of cancer treatment within the past 5 years. * Acute infectious diseases at the time of enrollment. * Severe liver dysfunction (e.g., cirrhosis, ALT/AST \>3× upper limit of normal). * Pregnancy or lactation. * Inability or unwillingness to provide informed consent. * Participation in another interventional clinical trial within the past 30 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiorenal syndrome (CRS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardio-renal syndrome congestive heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiorenal syndrome (CRS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Affiliated Hospital of Nantong University

    RECRUITING

    Nantong, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.